Introduction
The role of oxygen radicals and membrane lipid peroxidation in the pathophysiology of central nervous system ischaemia has become a major focus of research. While the provision of direct and unequivocal biochemical evidence has been hampered by methodological difficulties, recent biochemical, physiological and pharmacological approaches have strongly suggested a critical role for oxygen radicals in post-ischaemic neuronal degeneration [ 1-51. Potential sources of oxygen radicals following ischaemic injury to the brain or spinal cord include the enzyme xanthine oxidase, arachidonic acid metabolism, catecholamine oxidation, amine oxidase activity, mitochondria1 leakage, and activated white blood cells. The primary molecular target for oxygen radical damage appears to be membrane polyunsaturated fatty acids (i.e.
Abbreviation used: MCA, middle cerebral artery. lipid peroxidation), although oxidative damage to proteins may also be important.
Radical formation and lipid peroxidation are catalysed by free iron released from either of the iron storage proteins, transferrin and ferritin, a haemoglobin. Tissue acidosis is also a catalyst for iron release and lipid peroxidation. Membrane lipid peroxidation can contribute to injury-induced fatty acid release and calcium influx. In relation to the important role of calcium in secondary neural damage, lipid peroxidation can serve as an amplifier by increasing membrane permeability and/or impairing calcium extrusion mechanisms and mitochondrial sequestration [2] . Free radicals have also been demonstrated to facilitate the release of excitotoxic amino acid neurotransmitters [6] . Moreover, excitotoxic neuronal damage is likely to involve a free radical process as a downstream event in its mechanistic cascade [7] . Indeed, free radicalinduced lipid peroxidation may be the final common pathway of neuronal degeneration in cenFigure I tral nervous system ischaemia.
In addition to neurons and glia, vascular elements are particularly important sites of free radical-lipid peroxidative damage. A role for free radicals in injury-induced microvascular permeability and oedema formation, loss of autoregulation, hypoperfusion and vasospasm has been strongly supported by a variety of experimental investigations [3-51. Recent data shows that brain areas that are selectively vulnerable to ischaemic damage, such as the hippocampus, have higher baseline rates of oxygen radical generation [%lo] . Furthermore, the intensity of post-ischaemic generation of oxygen free radicals also parallels the selective vulnerability of the hippocampus [9, 101.
Perhaps the most compelling evidence for a role for oxygen radicals in secondary cerebral damage comes from the demonstration of the protective efficacy of free radical scavengers and lipid antioxidants in models of cerebral ischaemia. Although results from different studies vary, agents that are reported by some to have protective effects in models of focal and/or global ischaemia models include superoxide dismutase [ 11 -1 31, the xanthine oxidase inhibitors allopurinol [ 141 and oxypurinol [ 151, the hydroxyl radical scavengers dimethylthiourea [ 141 and dimethylsulfoxide [4] , the spintrapping agent phenylbutylnitrone [ 16, 171 and the lipid peroxyl radical scavenger a-tocopherol [ 18, 191. Recently, efforts have been undertaken to develop even more effective antioxidants that might ameliorate the secondary neural injury associated with stroke (i.e. focal ischaemia) or cardiac arrest (i.e. global ischaemia). A novel group of compounds, the 2 1-aminosteroids (lazaroids), has been designed; these are potent inhibitors of oxygen free radical-induced, iron-catalysed lipid peroxidation in nervous tissue [20, 211 . The rationale for these compounds was based upon the significant, but modest, ability of the glucocorticoid steroid methylprednisolone to inhibit lipid peroxidation. This steroid has recently been shown to significantly improve chronic recovery of spinal cord-injured patients, when administered within 8 h after injury in antioxidant doses, thus providing support for an antioxidant approach to cerebroprotection [22] . One of the 21-aminosteroids, tirilazad mesylate (U74006F; Figure l initial study using rat brain homogenates or purified rat brain synaptosomes as the lipid source, U74006F and U74500A potently inhibited irondependent lipid peroxidation, with an efficacy greatly surpassing that of the glucocorticoid steroid methylprednisolone [20, 21, 231 . These 2 l-aminosteroids have further been found to decrease ironinduced damage to cultured cortical neurons [24, 251. U74006F, which has been most extensively studied, appears to possess multiple antioxidant mechanisms. These include the following: (i) scavenging of lipid peroxyl radicals similar to the action of vitamin E [26] ; (ii) facilitation of the antioxidant properties of the endogenous lipid peroxidation inhibitor vitamin E [26] ; and (iii) scavenging of hydroxyl radicals [27] and membrane stabilization (i.e. decreased membrane fluidity) [28] . The last action probably provides the mechanistic explanation for the antioxidant properties of the glucocorticoid steroids such as methylprednisolone. Membrane stabilization would help to inhibit the propagation of lipid peroxidation by restricting the movement of peroxidized lipids within the membrane so that they are unable to attack the neighbouring polyunsaturated fatty acids.
Tirilazad mesylate efficacy in models of focal ischaemia
While increased oxygen radical formation is probably initiated during the ischaemic episode, it is greatly amplified following the re-oxygenation of the tissue after reperfusion [l-51. Thus, the most relevant context for evaluation of antioxidant compounds is the situation of ischaemia/reperfusion. Protective effects of the 21-aminosteroid U-74006F have been observed in several experimental models of focal cerebral ischaemia with reperfusion which mimic the clinical situation of thromboembolic stroke. First of all, in a model of temporary hemispheric cerebral ischaemia produced in the Mongolian gerbil by unilateral occlusion of a carotid artery, U74006F has been examined for its ability to promote survival and reduce neuronal necrosis [29] . Gerbils were pretreated with either vehicle or U74006F i.p. 10 min before and again immediately after a 3 h temporary occlusion of the right carotid artery. U74006F improved both 24-and 48-h survival compared with vehicle-treated animals. Histological examination of the brains of vehicle-treated animals at 24 h revealed marked neuronal cell loss (as much as 90% below control) in the hippocampus and lateral cerebral cortex. In contrast, the neuronal densities in the ischaemic hemisphere of gerbils treated with U74006F showed a doserelated and statistically-significant preservation of neurons in both brain regions.
Mechanistic studies have been undertaken in the same gerbil model to determine the effects of a double-dose 10 mg/kg i.p. regime of U74006F on post-ischaemic lipid peroxidation, measured in terms of both brain vitamin E depletion and recovery of cerebral cortical extracellular calcium (i.e. reversal of intracellular accumulation) [ 301. In both vehicle-and U74006F-pretreated gerbils, the vitamin E content of the ischaemic brain hemisphere was not affected after 3 h of carotid occlusion without reperfusion in relation to sham-occluded animals. This suggests that intraischaemic lipid peroxidation did not occur significantly. However, at 2 h following reperfusion in vehicle-treated gerbils, the vitamin E levels of the previously ischaemic hemisphere fell by an average of 60% compared with sham-occluded animals. In U74006F-treated gerbils, the post-ischaemic decrease in vitamin E was only 27.0% (P<0.002 versus vehicle).
Hemispheric ischaemia secondary to carotid occlusion (7.5% reduction in cerebral blood flow) resulted in a drop in extracellular calcium from 1.05f0.03 (S.E.M.) mM before ischaemia to 0.1 1 f 0.02 mM at 3 h in vehicle-treated gerbils. 
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These results provide evidence that the ability of the 21-aminosteroid antioxidant U74006F to reduce post-ischaemic neuronal degradation [29] is indeed due to an inhibition of post-ischaemic lipid peroxidation, as judged from the significant druginduced maintenance of endogenous vitamin E. A similar 2 h post-ischaemic preservation of ascorbic acid levels has also been observed in the presence of U74006F [31] . The most likely explanation is that, after the ischaemic insult, tissue vitamin E and ascorbate are being utilized to quench post-reperfusion membrane lipid peroxidative reactions, while U74006F spares tissue antioxidant content by assuming this responsibility. Secondary to this membrane protective mechanism, the drug acts to preserve cellular processes responsible for the reversal of the ischaemia-triggered intracelluar calcium accumulation. Figure 2 displays the correlation between preservation of brain vitamin E (i.e. inhibition of lipid peroxidation), enhancement of postischaemic recovery of cortical extracellular calcium and subsequent neuronal protection in the cortex and hippocampus.
In other work with the gerbil 3 h unilateral carotid occlusion model, Oostveen and Williams
[ 321 showed that U74006F attenuates neutrophil influx into the reperfused hemisphere [32] . Considering the production of oxygen radicals and other toxic products by neutrophils, a reduction in post-ischaemic infiltration is also likely to contribute towards the neuroprotective action. Indeed, these investigators showed a significant correlation between the extent of neutrophil infiltration and neuronal damage over a 24 h period after reperfusion.
U74006F has also been examined in the cat following a 1 h temporary occlusion of the middle cerebral artery (MCA) [33] . Beginning 15 min after occlusion release, U74006F was administered as a multiple bolus regme that was continued for 12 h.
At 1 week, using classic histological and quantitative 2-deoxy-glucose autoradiographic techniques, the area of cerebral infarction was assessed. Postischaemic treatment with U74006F significantly reduced the infarction volume compared with that in vehicle-treated cats. However, in another cat study employing a longer period of temporary MCA occlusion (3 h), no effect of the compound was observed [34] . In contrast, a near complete prevention of 3 h post-ischaemic brain oedema has been reported in cynomolgous monkeys subjected to 3 h of MCA occlusion but treated with U74006F (3 mg/kg i.v.) 10 min prior to reperfusion [35] .
The compound has also been shown to reduce infarct size in a rat model of temporary
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Free Radical Damage and Antioxidant Intervention MCA occlusion [ 361. In Wistar rats pretreated with a 10 mg/kg i.v. dose followed by a 2 h episode of MCA occlusion, there was a 67.3% reduction in the 24 h post-ischaemic infarct volume compared with vehicle-pretreated rats. The same study demonstrated a 25% reduction in infarct size in a model of 2 h of MCA occlusion plus 24 h of reperfusion in spontaneously hypertensive rats. U74006F has also been evaluated in a baboon model of 3 h of MCA occlusion plus 2 weeks of post-ischaemic reperfusion (E. Mori and G. Del Zoppo, personal communication). U74006F was administered at 15 min prior to reperfusion and at 2, 4, 12 and 24 h afterwards. Two week infarct volume in the cortex and underlying white matter was reduced by 50% compared with vehicle-treated baboons. Although this effect was not statistically significant (P< 0.163), analysis of infarct area near the centre of the infarct did reveal a significant decrease in the U74006F-treated animals. An early and persistent improvement in neurological score was also associated with U74006F treatment. In addition to showing efficacy in models of focal ischaemia with reperfusion, U74006F has been documented to reduce infarct size and/or oedema in Sprague-Dawley rats subjected to permanent MCA occlusion . This implies that the relevance of free radical mechanisms and thus antioxidant protection is not totally confined to ischaemic situations in which reperfusion takes place. However, it should be pointed out that the compound has not shown efficacy in a model of permanent MCA occlusion in spontaneously hypertensive rats [36] .
Tirilazad mesylate emcacy in models of global ischaemia
In models of global cerebral ischaemia with reper-fusion, which mimic the clinical situation of cardiac arrest/resuscitation, U74006F has produced mixed, but general positive results. A reduction in delayed (7 days) post-ischaemic hippocampal CAI damage has been observed in the widely used gerbil brief bilateral carotid occlusion model, but only with maintained dosing as displayed in Figure 3 ; acute peri-ischaemic dosing is ineffective [40] . In the rat model of brief (1 0-12 min) bilateral carotid occlusion plus hypotension, an improved recovery of brain energy metabolism has been reported [41] , as well as a reduction in cortical histopathology [42] . Although the highly sensitive hippocampus has not been effectively protected by U74006F in the same model [42, 431 or in the rat 15 min four-vessel occlusion model [44] , the doses examined so far in the rat are much lower than the dose found to salvage the gerbil hippocampus. This discrepancy between antioxidant protection of the cortex and the hippocampus has led to the suggestion that the mechanisms of post-ischaemic neuronal damage may differ in those two regions, with lipid peroxidation being more relevant in the cortex. However, the mixed results with U74006F in regards to its ability to successfully impact the cortical damage associated with brief global ischaemia [42] , but not the more severe hippocampal damage (particularly the highly vulnerable CAI region) , may be explained by the observations of accentuated postischaemic free radical production and lipid peroxidation in the hippocampus in comparison to the cortex [8-lo] . Thus, the exploration of tirilazad doses as high as those utilized in the gerbil, or the administration of the compound preferably by the i.v. route at the time of reperfusion, may produce better protection in the hippocampus than has been reported to date. It should also be pointed out that, in addition to U74006F [40] , other free radical scavengers or lipid antioxidants have also been reported to effectively reduce post-ischaemic neuronal damage to the gerbil hippocampus [13, 15, 16, 18, 191 . Interestingly, in a more severe neonatal rat 2 h hypoxic-ischaemic model, U74006F has shown a highly significant reduction of histopathology even when administered at the end of the hypoxic ischaemic insult [45] . Moreover, in a dog cardiac arrest model, U74006F has been documented to improve neurological recovery and survival [46] . The compound has also been found to improve early neurological [47] and metabolic [48] recovery in dog models of brief global ischaemia produced via raised intra-cranial pressure.
Other antioxidant compounds
A second generation of lazaroids that are much more potent and effective antioxidants than the 2 1 -aminosteroids has been discovered. These compounds couple the amino functionality of tirilazad with the 2-methylaminochroman ring structure of vitamin E. One of these compounds, U785 17F, consistent with its greater antioxidant potency, exerts a predictably more potent protective action than U74006F (tirilazad mesylate) in gerbil models of focal and global cerebral ischaemia [25, 49] .
Although further work is required to gain an understanding of oxygen radical involvement in cerebral ischaemic pathophysiology and pathology, the repeatedly demonstrated efficacy of free radical scavenging or lipid antioxidant compounds strongly points toward an important role for oxygen radical mechanisms in post-ischaemic brain damage.
